Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

[Comprehensive Genomic Analysis for Small Cell Lung Cancer].

Yuji Shibata1, Hibiki Udagawa, Shingo Matsumoto

  • 1Dept. of Thoracic Oncology, National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 12, 2021
PubMed
Summary

Genomic analysis of Japanese small cell lung cancer (SCLC) patients identified PI3K/AKT/mTOR pathway alterations. A subsequent clinical trial evaluated targeted therapy efficacy for these SCLC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same author

Development of machine learning models to determine CO<sub>2</sub> seepage in the ocean based on the seepage and non-seepage database.

Marine pollution bulletin·2026
Same author

Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistance.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026
Same author

Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026

Area of Science:

  • Oncology
  • Genomics
  • Translational Medicine

Background:

  • Small cell lung cancer (SCLC) has a poor prognosis and is often diagnosed at advanced stages.
  • Key genetic alterations in SCLC include TP53/RB1 mutations and MYC amplifications, but actionable targets for therapy remain limited.
  • Recent genomic analyses have begun to uncover potential therapeutic targets in SCLC.

Purpose of the Study:

  • To conduct a large-scale genomic analysis of Japanese SCLC patients (LC-SCRUM-Japan).
  • To evaluate the efficacy of targeted therapy for SCLC with PI3K/AKT/mTOR pathway gene alterations (EAGLE-PAT trial).
  • To provide an overview of SCLC genetic alterations and targeted therapy development.

Main Methods:

  • Prospective, large-scale genomic screening of Japanese SCLC patients.

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

605
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.9K

Related Experiment Videos

Last Updated: Nov 6, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

605
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.9K
  • Conducting a clinical trial (EAGLE-PAT) to assess targeted therapy in patients with specific gene alterations.
  • Reviewing existing literature on SCLC genetic alterations and targeted therapies.

    • Main Results:

    • Identification of PI3K/AKT/mTOR pathway gene alterations in Japanese SCLC patients.
    • Evaluation of targeted therapy efficacy in the EAGLE-PAT trial for patients with these alterations.
    • Comprehensive overview of SCLC genomic landscape and therapeutic strategies.

    Conclusions:

    • Genomic profiling is crucial for identifying actionable targets in SCLC.
    • Targeted therapies for PI3K/AKT/mTOR pathway alterations show promise in SCLC.
    • Further research into SCLC genetics and targeted therapies is warranted.